Immune checkpoints: A therapeutic target in triple negative breast cancer

Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple nega...

Descripción completa

Detalles Bibliográficos
Autores principales: Chawla, Akhil, Philips, Anne V, Alatrash, Gheath, Mittendorf, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022604/
https://www.ncbi.nlm.nih.gov/pubmed/24843833
http://dx.doi.org/10.4161/onci.28325
Descripción
Sumario:Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.

Ejemplares similares